Brind.
  1. The FDA approved the Biologics License Application (BLA) for LEQEMBI IQLIK on August 30, 2025, involving companies headquartered in Cambridge and Tokyo.

FDA approved subcutaneous dose for lecanemab initiation.

1 report, 1 independent Updated Jul 17
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

FDA approved subcutaneous dose for lecanemab initiation.

Who's involved

What this event is mainly about
FDAEisai

Keep exploring

Part of

The FDA approved the Biologics License Application (BLA) for LEQEMBI IQLIK on August 30, 2025, involving companies headquartered in Cambridge and Tokyo. All 2 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped